키실로메타졸린
Xylometazoline
데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
기본 정보
- CAS
526-36-3- 표준 SMILES
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1- InChIKey
HUCJFAOMUPXHDK-UHFFFAOYSA-N- 분자식
- C16H24N2
- 평균 분자량
- 244.37 g/mol
- 단동위원소 질량
- 244.19394877
개요
Xylometazoline is an alkylbenzene.
이름 및 식별자
- 우선 이름
- Xylometazoline
- IUPAC
- 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
- 현지명
- 키실로메타졸린
- 영어명
- 2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE
- 분자식
- C16H24N2
- 분자량
- 244.38
이름 및 동의어
xylometazoline526-36-3XylomethazolineOtrivenXilometazolina2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazoleXylometazolinumBalminilWPY40FTH8K2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline1H-Imidazole, 2-((4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methyl)-4,5-dihydro-DTXSID8046957
이름 더 보기
키실로메타졸린자일로메타졸린자일로메타졸린및그염류OtrixOtrivinBa-11391OtrivineRhinoxilinAKOS BBS-00000259XYLOMETAZOLINEANDITSHYDROCHLORIDE
1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-stasNasanOtrivin MentolNasentropfen ALNasenspray AL2-((4-tert-butyl-2,6-dimethylphenyl)methyl)-4,5-dihydro-1H-imidazoleNasenSpray ratiopharm
데이터베이스 식별자
- CAS
526-36-3- PubChem CID
- 5709
- DTXSID
DTXSID8046957- ChEMBL
CHEMBL312448- ChEBI
CHEBI:10082- UNII
- WPY40FTH8K
- EC Number
- 208-390-6
- Nikkaji
- J6.660E
물성
구조 계산 물성보충 중
- XLogP
- 3.2
- 극성 표면적
- 24.4 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 1
- 회전 가능 결합 수
- 3
- 무거운 원자 수
- 18
- 형식 전하
- 0
- 복잡도
- 302
실험 및 물리화학적 성질
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceutical
Pharmaceuticals
LogP3.2
Human Drugs
Breast Feeding; Lactation; Milk, Human; Adrenergic alpha-Agonists; Sympathomimetics; Nasal Decongestants
Pharmaceuticals
Ear, nose and throat medicines [c]
Melting Point
317-329
131 - 133 °C
Physical DescriptionSolid
Collision Cross Section
161.58 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
170.4 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
물리화학적 성질
- 녹는점
- 131 · 131-133°
- 끓는 점
- 394.2 · 394.2±21.0 °C(Predicted)
- 밀도
- 1 · 1.00±0.1 g/cm3(Predicted)
- 저장 조건
- -20 °C · Store at -20°C
- 용해도
- 49 mg/mL · DMSO: 49 mg/mL (200.51 mM);Ethanol: 49 mg/mL (200.51 mM)
- 산도 계수 (pKa)
- 10.6 · pKa 10.6±0.1(H2O t = 22.0) (Uncertain)
- 수용성
- Water: Insoluble
- InChI
- InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
- InChIKey
- HUCJFAOMUPXHDK-UHFFFAOYSA-N
- SMILES
- C1(CC2=C(C)C=C(C(C)(C)C)C=C2C)NCCN=1
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
유해성 정보
Regulatory InformationChemical: 1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-
Other Safety InformationIMAP assessments - 1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-: Environment tier I assessment
독성 정보
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Xylometazoline
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
안전 데이터
- 독성
- LD50 oral in mouse: 215mg/kg
화학 및 산업
약리 정보
ATC Code
R01AA07
R - Respiratory system
R - Respiratory system
S - Sensory organs
QR - Respiratory system
QR - Respiratory system
Protein BindingNo information is available on xylometazoline pharmacokinetics.
Pharmacodynamics
Xylometazoline is a sympathomimetic agent that causes vasoconstriction of the nasal mucosa. In one study comprising subjects with nasal congestion associated with the common cold, the median time of onset of subjective relief of nasal congestion was about 1.7 minutes and the time of subjective peak relief of nasal congestion was 30 minutes. Previous studies reported rebound swelling, rebound nasal congestion, rhinitis medicamentosa, and shorter duration of decongestant effect from the long-term use of xylometazoline in healthy volunteers, suggesting that the drug is most effective if used temporarily. An early _in vitro_ study demonstrated xylometazoline to exert anti-oxidant actions, where it inhibited microsomal lipid peroxidation and mediated hydroxyl radical scavenging activity. This suggests that xylometazoline has a beneficial effect against oxidants, which play a role in tissue damage in inflammation.
Mechanism of Action
Nasal congestion is caused by various etiologies, such as rhinosinusitis and allergic or non-allergic rhinitis, leading to congestion of the venous sinusoids lining the nasal mucosa. Activation of α-adrenergic receptors leads to vasoconstriction of the blood vessels of the nasal mucosa and resumption of nasal airflow. As the most abundantly expressed in the human nasal mucosa, α<sub>1A</sub>- and α<sub>2B</sub>-adrenoceptors may play the most important role in vasoconstriction of the human nasal mucosa. Xylometazoline is a more selective agonist at α<sub>2B</sub>-adrenoceptors, with affinity at α<sub>1A</sub>-, α<sub>2A</sub>-, α<sub>2C</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-adrenoceptors. Xylometazoline decreases nasal resistance during inspiration and expiration and increases the volume of nasal airflow. Compared to [oxymetazoline], another imidazoline nasal decongestant, xylometazoline had a slightly faster onset of action although they had a similar duration of action. In one study, subjects with nasal congestion reported relief of earache and sore throat in addition to nasal decongestion: it is speculated that oxymetazoline mediates this effect by causing vasoconstriction of the nasal mucosa that contains the venous sinuses and nasal decongestion allows breathing through the nose, providing relief from sore throat caused by mouth breathing that dries and irritates the throat.
Biological Half-LifeNo information is available on xylometazoline pharmacokinetics.
Metabolism/MetabolitesNo information is available on xylometazoline pharmacokinetics.
MeSH Pharmacological Classification
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)
Drugs used to cause dilation of the blood vessels.
Absorption, Distribution and Excretion
No information is available on xylometazoline pharmacokinetics.
No information is available on xylometazoline pharmacokinetics.
No information is available on xylometazoline pharmacokinetics.
No information is available on xylometazoline pharmacokinetics.
Cellular LocationsExtracellular
용도 및 제조
UsesUse (kg; approx.) in Germany (2009): >250
Use ClassificationPharmaceuticals
응용 분야
용도Adrenergic (vasoconstrictor).
관련 반응
4건
화합물 노트
불러오는 중…